Advanced in Malnutrition

Dr. Rohit Jain

Endocrinology
Gw Endocrinology-West End: 2300 M Street
2300 M St NW # 9, 
Washington, DC 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth

Advanced in Malnutrition
Gw Endocrinology-West End: 2300 M Street
2300 M St NW # 9, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rohit Jain is an Endocrinologist in Washington, Washington, D.c.. Dr. Jain is rated as an Advanced provider by MediFind in the treatment of Malnutrition. His top areas of expertise are Muscle Invasive Bladder Cancer, Milk-Alkali Syndrome, Hypercalcemia, Penectomy, and Endoscopy.

His clinical research consists of co-authoring 342 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Malnutrition.

Specialties
Endocrinology
Licenses
Internal Medicine in MD
Hospital Affiliations
George Washington Univ Hospital
Suburban Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Gw Endocrinology-West End: 2300 M Street
2300 M St NW # 9, Washington, DC 20037
Call: 202-741-3422

Additional Areas of Focus

Dr. Jain has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


11 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations
Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug
Study Drugs: Enfortumab Vedotin, Erdafitinib
Study Phase: Phase 1
Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma
Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Sacituzumab govitecan
Study Phase: Phase 1/Phase 2
A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)
A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2025
Intervention Type: Drug
Study Drugs: CG0070, Nivolumab
Study Phase: Phase 1
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Abiraterone Acetate
Study Phase: Early Phase 1
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Early Phase 1
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Lirilumab
Study Phase: Phase 1
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Procedure, Other, Biological, Drug
Study Drugs: Atezolizumab, Glycosylated Recombinant IL-7
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Enrollment Status: Completed
Publish Date: April 27, 2022
Intervention Type: Biological
Study Drugs: CV-301, Atezolizumab
Study Phase: Phase 2
View 10 Less Clinical Trials

342 Total Publications

The Synergy of Percutaneous Coronary Intervention and Lifestyle Modification in Reducing Mortality and Blockage Prevention.
The Synergy of Percutaneous Coronary Intervention and Lifestyle Modification in Reducing Mortality and Blockage Prevention.
Journal: Cardiology in review
Published: December 08, 2025
View All 342 Publications
Similar Doctors
Todd T. Brown
Advanced in Malnutrition
Dr. Todd T. Brown
Endocrinology
Advanced in Malnutrition
Dr. Todd T. Brown
Endocrinology

Johns Hopkins Outpatient Center

601 North Caroline Street, Floor 7, Floor 7, 
Baltimore, MD 
 (33.5 miles away)
410-955-9270
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Todd T. Brown, MD, PhD is a clinical investigator who focuses on body composition, metabolic, and skeletal abnormalities observed in people with HIV, particularly as related to aging. Through translational investigation, epidemiologic studies, and clinical trials, he has been interested in understanding the pathogenesis of glucose disorders, fat changes, hormonal dysregulation, and osteoporosis in people with HIV, the consequences of these conditions (eg cardiovascular disease, frailty), and their optimal evaluation and management. Dr. Brown is rated as an Advanced provider by MediFind in the treatment of Malnutrition. His top areas of expertise are Low Blood Sugar, Osteoporosis, Malnutrition, Gastric Bypass, and Gastrostomy.

Advanced in Malnutrition
Dr. Iris Hartley
Endocrinology
Advanced in Malnutrition
Dr. Iris Hartley
Endocrinology

Dept Of Transfusion Medicine/Nih Clinical Center

10 Center Dr, 
Bethesda, MD 
 (0.5 miles away)
301-496-6821
Languages Spoken:
English
See accepted insurances

Iris Hartley is an Endocrinologist in Bethesda, Maryland. Dr. Hartley is rated as a Distinguished provider by MediFind in the treatment of Malnutrition. Her top areas of expertise are Autosomal Dominant Hypocalcemia, Osteomalacia, Rickets, and Calcinosis.

Advanced in Malnutrition
Dr. Hilary Whitlatch
Endocrinology
Advanced in Malnutrition
Dr. Hilary Whitlatch
Endocrinology

UMMC Nephrology

800 Linden Ave Fl 8, 
Baltimore, MD 
 (33.3 miles away)
443-682-6800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hilary Whitlatch is an Endocrinologist in Baltimore, Maryland. Dr. Whitlatch is rated as an Advanced provider by MediFind in the treatment of Malnutrition. Her top areas of expertise are Rabson-Mendenhall Syndrome, Hyperparathyroidism, Osteoporosis, and Postmenopausal Osteoporosis.

VIEW MORE MALNUTRITION DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
  • Elite
  • Muscle Invasive Bladder Cancer
    Dr. Jain is
    Elite
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
    • Advanced
    • Hypercalcemia
      Dr. Jain is
      Advanced
      . Learn about Hypercalcemia.
      See more Hypercalcemia experts
    • Malnutrition
      Dr. Jain is
      Advanced
      . Learn about Malnutrition.
      See more Malnutrition experts
    • Maturity Onset Diabetes of the Young
      Dr. Jain is
      Advanced
      . Learn about Maturity Onset Diabetes of the Young.
      See more Maturity Onset Diabetes of the Young experts
    • Milk-Alkali Syndrome
      Dr. Jain is
      Advanced
      . Learn about Milk-Alkali Syndrome.
      See more Milk-Alkali Syndrome experts
    • Thyroid Storm
      Dr. Jain is
      Advanced
      . Learn about Thyroid Storm.
      See more Thyroid Storm experts
    • Type 1 Diabetes (T1D)
      Dr. Jain is
      Advanced
      . Learn about Type 1 Diabetes (T1D).
      See more Type 1 Diabetes (T1D) experts
    View All 7 Advanced Conditions
    • Experienced
    • Addison's Disease
      Dr. Jain is
      Experienced
      . Learn about Addison's Disease.
      See more Addison's Disease experts
    • Anaplastic Thyroid Cancer
      Dr. Jain is
      Experienced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    • Cardiofaciocutaneous Syndrome
      Dr. Jain is
      Experienced
      . Learn about Cardiofaciocutaneous Syndrome.
      See more Cardiofaciocutaneous Syndrome experts
    • Colonoscopy
      Dr. Jain is
      Experienced
      . Learn about Colonoscopy.
      See more Colonoscopy experts
    • Diabetic Retinopathy
      Dr. Jain is
      Experienced
      . Learn about Diabetic Retinopathy.
      See more Diabetic Retinopathy experts
    • Endoscopy
      Dr. Jain is
      Experienced
      . Learn about Endoscopy.
      See more Endoscopy experts
    View All 46 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.